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Chapter I 
Preface 
 
Control over a protein function by small-molecule as a therapeutic approach 
generally targets a binding site of an endogenous metabolite or a small ligand in an 
enzyme or receptor protein, respectively. On the other hand, proteins which consist of 
large protein–protein interaction interfaces and lack a deep pockets, many of 
transcription factors and splicing factors, are often deemed as an undruggable target in 
medicinal chemistry1. Therefore, targeting protein metabolism, including synthesis and 
degradation of proteins, is now considered as a desirable strategy for disrupting such 
undruggable proteins in cells. Small interfering RNA (siRNA) drug is one of the options 
to down-regulate the target protein abundance in human tissue. However, the currently 
available delivery system for siRNA to target tissue is limited2.  
The ubiquitin-proteasome system is a key mechanism of the regulated protein 
degradations in mammalian cells. The recent successes of proteasome inhibitors as the 
multiple myeloma drug proved the therapeutic potential of targeting the proteolysis3. 
More recently, clinically important myeloma drug lenalidomide and other 
immune-modulatory drugs (IMiDs) were reported to hijack cullin-4 RING ubiquitin 
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ligase by binding to the one of DDB and CUL4-associated proteins (DCAFs), cereblon 
(CRBN), to redirect the substrate selectivity of the ligase4-7. As a results of the 
reprograming of ubiquitin ligase activity, lenalidomide induces the proteasomal 
degradation of the transcription factors IKZF1, IKZF3 and casein kinase 1α in cells. 
In Chapter II, I revealed the mechanism underlying anticancer activity of a 
series of sulfonamide derivatives, E7820, indisulam, and chloroquinoxaline sulfonamide 
(CQS)8. Based on the mass spectrometry-based proteomics, I demonstrated that 
anticancer sulfonamides induce protein complex assembly between U2AF related 
splicing factor, CAPERα, and an ubiquitin ligase, CRL4DCAF15. This small chemical 
induced protein complex assembly results in selective ubiquitination and proteasomal 
degradation of the splicing factor to induce aberrant mRNA splicing and subsequent 
anti-proliferative effect in cancer cell lines. The molecular mechanism of these 
sulfonamides, in addition to that of IMiDs, suggests DCAFs are promising drug targets 
through the promotion of selective protein degradation (Figure I-1). 
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Figure I-1. Mechanism of the target protein degradation by the small chemicals. 
Immunomodulatory drugs (IMiDs) bind to one of DDB1 and CUL4-associated factors 
(DCAFs), CRBN. Binding of IMiDs reprograms the substrate selectivity of CRL4CRBN 
to induce ubiquitination of IKZF1, IKZF3, and CK1α. These ubiquitinated proteins are 
subsequently degraded by proteasome. Anticancer sulfonamide derivatives bind to 
DCAF15 to recruit and ubiquitinate the splicing factor CAPERα. Ubiquitinated 
CAPERα is also degraded by proteasome. 
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Chapter II 
Selective Degradation of Splicing Factor CAPERα  by 
Anticancer Sulfonamides 
 
Summary 
Target protein degradation is an emerging field in drug discovery and 
development. In particular, the substrate receptor proteins of the cullin ubiquitin ligase 
system play a key role in selective protein degradation, which is an essential component 
of the anti-myeloma activity of immunomodulatory drugs (IMiDs) represented by 
lenalidomide. Here, I demonstrate that a series of anticancer sulfonamides NSC 719239 
(E7820), indisulam, and NSC 339004 (chloroquinoxaline sulfonamide, CQS) induce 
proteasomal degradation of an U2AF-related splicing factor, Coactivator of Activating 
Protein-1 and Estrogen Receptors (CAPERα) via CRL4DCAF15 mediated ubiquitination 
in human cancer cell lines. Both CRISPR/Cas9-based knockout of DCAF15 and a 
single amino acid substitution of CAPERα conferred resistance against 
sulfonamide-induced CAPERα degradation and cell-growth inhibition. Thus, these 
sulfonamides represent selective chemical probes for disrupting CAPERα function and 
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designate DCAFs as promising drug targets for promoting selective protein degradation 
in cancer therapy. 
 
Introduction 
 Protein metabolism, including protein ubiquitination and proteasomal 
degradation, has recently been discovered to be an important therapeutic modality for 
cancer. The proteasome inhibitor bortezomib has shown significant efficacy in the 
treatment of multiple myeloma, and the protein NEDDylation inhibitor MLN4924 is in 
clinical trials3,9,10. Furthermore, the myeloma drug lenalidomide (Figure II-1) was 
reported to target one of the DDB1- and CUL4-associated factors (DCAFs), cereblon 
(CRBN), and to induce selective degradation of the Ikaros family zinc finger proteins 1 
and 3 (IKZF1 and IKZF3) and casein kinase 1α (CK1α) as key mechanisms of 
anticancer activity in multiple myeloma cells and the deletion 5q (del (5q)) subtype of 
myelodysplastic syndromes (MDS)4-7,11-14. CRBN and other DCAFs are components of 
the CUL4-RING ubiquitin ligase (CRL4) complex, and play a central role in substrate 
recognition for ubiquitination15-17. Furthermore, recent reports show that conjugation of 
the phthalimide moiety of thalidomide with a competitive antagonist of BET 
bromodomains induces the degradation of transcriptional coactivator BRD4 via 
CRL4CRBN, suggesting that CRBN-based target protein degradation may also be 
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applicable to substrate proteins other than IKZF1 and IKZF3, and thus an accessible 
therapeutic strategy using chemical conjugation techniques18-22. 
 Here, I initiated a target identification study for a series of anticancer 
sulfonamides NSC 719239 (E7820, 1), indisulam (2), and NSC 339004 
(chloroquinoxaline sulfonamide, CQS, 3) (Figure II-1), based on observations that they 
may have clinical activity in cancer patients23-25. CQS and indisulam are chlorinated 
heterocyclic sulfonamide derivatives, and have unique mean-graph fingerprints in an 
NCI COMPARE analysis that are quite different from those of other anticancer drugs in 
clinical use (https://dtp.cancer.gov/databases_tools/compare.htm)26, whereas E7820 has 
been shown to be a novel anticancer and anti-angiogenesis agent that inhibits VEGF- or 
FGF-2-induced tube formation of human umbilical endothelial cells (HUVEC)27. 
Although these sulfonamides have been the focus of drug discovery and development 
efforts over the past two decades, the primary target molecule and their precise 
mechanisms of action remain unclear28-30. I recently found that an indisulam-resistant 
clonal cancer cell line was cross-resistant to E7820 and CQS, but not doxorubicin and 
paclitaxel (Figure II-2)28. This suggests that the drug resistant mechanism is 
independent of P-glycoprotein-based multi-drug resistance (MDR) and associated with 
a mechanism of anticancer action which is common in these three sulfonamides.  
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 In the present study, I report that E7820, indisulam, and CQS promote selective 
degradation of an U2AF-related splicing factor, Coactivator of Activating Protein-1 and 
Estrogen Receptors (CAPERα) by inducing protein complex assembly between 
CAPERα and CRL4DCAF15. A single amino acid substitution of CAPERα conferred 
resistance against sulfonamide-induced CAPERα degradation and cell-growth 
inhibition, suggesting that CAPERα degradation is a key biochemical activity that 
underlies the anticancer properties of these compounds. 
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Results 
Down-regulation of CAPERα  by E7820, indisulam, and CQS 
 To clarify the cellular effect of E7820 at an early time point, I used a label-free 
quantitative proteome analysis strategy, Data-Independent Acquisition (DIA)31. In 
traditional Data-Dependent Acquisition (DDA) with a certain isobaric labeling 
technique, mass spectrometer randomly samples detectable peptides for fragmentation, 
often resulting in insufficient reproducibility. In DIA, all precursor ions are 
systematically fragmented with defined m/z windows, allowing highly reproducible 
quantification of peptides. Differential profiling of the cellular proteins in cells treated 
with E7820 and dimethyl sulfoxide (DMSO) demonstrated that there were significant 
decreases in CAPERα in both the human colon colorectal carcinoma cell line HCT116 
and the human myelogenous leukemia cell line K562 6 hours after treatment with 
E7820 (Figure II-3a). In vitro staining of HCT116 cells showed that CAPERα 
co-localizes with SC35 in the nuclear speckle, as previously reported32, and that there is 
a clear reduction in the CAPERα signal following E7820 treatment (Figure II-3b). I 
then compared the effects of E7820, indisulam, and CQS on CAPERα protein 
expression by performing immunoblot analysis to confirm the reduction of CAPERα is 
a common biochemical consequence among these molecules. There was a good 
correlation between the extent of CAPERα reduction and cell-growth inhibition for all 
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three sulfonamides (Figure II-3c, Table 1). A quantitative polymerase chain reaction 
(qPCR) assay further demonstrated that the mRNA expression of CAPERα increased 
following the protein reduction in both HCT116 and K562 cells (Figure II-3d, 3e), 
suggesting protein down-regulation by these sulfonamides is posttranscriptional and the 
gene expression of CAPERα may be negatively regulated by CAPERα protein. 
 
 CAPERα  degradation depends on CRL4DCAF15 
 To examine whether this sulfonamide-induced CAPERα reduction is 
dependent on cullin-RING ubiquitin ligase (CRL), I assessed the effect of MLN4924, a 
small molecule inhibitor of NEDD8-activating enzyme (NAE), on protein reduction, 
since CRL activity depends on NEDDylation9. I found that MNL4924 completely 
blocked E7820-induced reduction of CAPERα, as did the myeloma drug bortezomib, a 
selective proteasome inhibitor (Figure II-4a), indicating that E7820 induces 
CRL-mediated ubiquitination and proteasomal degradation of CAPERα. Therefore, I 
hypothesized that these sulfonamides induce a protein-protein interaction between 
CAPERα and the CRL complex. 
 To identify the binding partner of CAPERα, I used CAPERα 
immunoprecipitation followed by DIA. Differential proteome analysis demonstrated 
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that E7820 enhances the ability of CAPERα to bind to DCAF15 and DDB1 in both 
HCT116 and K562 cells (Figure II-4b). DDB1 functions as a linker between the CUL4 
scaffolds and DCAF substrate receptors to build the CRL4 complexes, which regulate 
diverse protein ubiquitination and cellular functions16,17. To confirm whether 
DCAF15-DDB1 plays a key role in CAPERα degradation, I performed a 
siRNA-mediated knockdown of DCAF15 and DDB1 in HCT116 cells. As expected, 
both DCAF15 and DDB1 knockdowns rescued sulfonamide-induced CAPERα 
degradation and inhibition of cell growth in HCT116 cells (Figure II-5). Since DDB1 
functions as a general linker protein in the CRL4 complex, I suspected that DCAF15 
might be a more suitable protein target for compound mediated selective protein 
degradation. Therefore, I established a DCAF15 knockout clone of HCT116 using 
CRISPR/Cas9-based gene editing (Figure II-6). An immunoblot analysis and cell 
viability assay revealed that DCAF15-/- HCT116 cells were also resistant to 
sulfonamide-induced CAPERα degradation and cell-growth inhibition in spite of strong 
growth inhibition by other cytotoxic agents (Figure II-7, Figure II-8). Unfortunately, I 
was unable to identify the cullin protein(s) because there were insufficient differences 
between compound-induced interactions and non-specific binding of cullin protein 
under these immunoprecipitation conditions. Therefore, I next assessed the effect of 
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CUL4A and/or CUL4B knockdown on CAPERα degradation. Interestingly, the double 
knockdown of CUL4A and CUL4B significantly prevented E7820-induced CAPERα 
degradation, whereas the single knockdown of either CUL4A or CUL4B did not (Figure 
II-9), indicating that CUL4A and CUL4B may be involved in 
DCAF15-DDB1-mediated protein ubiquitination in a redundant manner17,33. 
 
DCAF15 is the primary target of anticancer sulfonamides 
 The stable transfection of DCAF15 into DCAF15-/- HCT116 clonal cells 
successfully restored the E7820-induced protein degradation (Figure II-10a). Therefore, 
I examined the identity of the molecular complex that includes E7820, CAPERα, 
DCAF15, and DDB1 using DCAF15- or mock-vector-transfected DCAF15-/- HCT116 
cells. Immunoprecipitation with the anti-CAPERα antibody followed by immunoblot 
analysis confirmed that E7820 induces protein complex assembly between CAPERα 
and DCAF15-DDB1. The antibody did not pull down DDB1 in the mock-transfected 
cells but did in the DCAF15-transfected cells following E7820 treatment, indicating that 
DDB1 binds to CAPERα via DCAF15 (Figure II-10b). In addition, CAPERα 
immunoprecipitation followed by an ubiquitin immunoblot analysis confirmed that 
E7820-induced CAPERα ubiquitination is dependent on DCAF15 (Figure II-10C). Next, 
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I immunoprecipitated CAPERα from tritium-labeled E7820 (3H-E7820, 4, Figure II-1) 
treated HCT116 cells with or without cold E7820 competition. The anti-CAPERα 
antibody captured a strong tritium count from the DCAF15-transfected cells, but not 
from the mock-transfected or cold E7820 competed cells, indicating that the E7820 
molecule is present in the CAPERα-DCAF15-DDB1 complex (Figure II-10d). To 
identify a direct binding partner for E7820, I performed photo-affinity labeling with a 
biotinylated photoactive E7820 probe (5, Figure II-1). Photo-affinity labeling followed 
by biotin-streptavidin affinity purification selectively captured and enriched DCAF15, 
with E7820, indisulam, and CQS all competing for probe binding to DCAF15 (Figure 
II-10e). Together, these findings demonstrate that these three sulfonamides induce 
protein complex assembly between CAPERα and CRL4DCAF15, thereby promoting 
ubiquitination and proteasomal degradation of CAPERα. Moreover, the deleterious 
effect of DCAF15 knockdown on HCT116 cell growth indicates that the 
anti-proliferative activities of these sulfonamides are not caused by simple antagonism 
toward DCAF15 (Figure II-5c). 
The biochemical activity of these sulfonamides might be similar to that of 
lenalidomide5,6. Therefore, I assessed the cross-reactivity of small-molecule-mediated 
protein degradation between E7820 and lenalidomide in the multiple myeloma cell line 
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MM.1S. E7820 treatment resulted in the clear degradation of CAPERα but did not 
affect the expression of IKZF1 or IKZF3 in the MM.1S cells. By contrast, lenalidomide 
did not decrease CAPERα expression at a concentration of 10 µM, which is sufficient 
for IKZF1 and IKZF3 degradation (Figure II-11). These results verify the specific 
protein degradations of E7820 and lenalidomide are independent and not cross-reactive. 
 
CAPERα  degradation is crucial for anticancer activity 
I also performed differential exome sequencing of parental HCT116 cells and 
sulfonamide-resistant clonal cells established by serial exposure to a drug concentration 
escalation procedure (Figure II-2)28. Exome sequencing detected 17 differential gene 
mutations in the sulfonamide-resistant cells, including a heterozygous G268V/missense 
mutation in CAPERα and a heterozygous R87* nonsense mutation (Figure II-12, Table 
2). To investigate the mutational status of the CAPERα protein in the 
sulfonamide-resistant cells, I analyzed immunoprecipitated CAPERα using liquid 
chromatography-tandem mass spectrometry (LC-MS/MS), which demonstrated that the 
G268V mutant CAPERα was dominantly expressed in resistant cells (Figure II-13). I 
also found that E7820 did not degrade CAPERα in the resistant cells (Figure II-14) and 
did not enhance the protein-protein interaction between DCAF15/DDB1 and CAPERα 
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(Figure II-15). Therefore, I hypothesized that the G268V mutation confers resistance to 
E7820-induced CAPERα degradation and cell-growth inhibition. To test this hypothesis, 
I used CRISPR/Cas9-based gene editing to establish CAPERα-G268V mutant cells, 
which were then treated with E7820. As expected, gene sequencing revealed that the 
E7820 treatment enriched the G268V mutant cells in all transfectants (Figure 16). 
Therefore, I performed cell cloning and selected clonal cells which have heterozygous 
CAPERα-G268V mutations for further investigation (Figure II-16). Immunoblot 
analysis showed that these K562-G268V mutant cells exhibited sulfonamide-induced 
incomplete degradation of CAPERα (Figure II-17). Notably, an 
immunoprecipitation-LC-MS/MS analysis of CAPERα demonstrated that both wild 
type and G268 mutant CAPERα proteins are co-expressed in K562-G268V mutant cells, 
and that only the wild type protein is degraded by E7820, resulting in the retention of 
the mutant protein (Figure II-18). The nuclear magnetic resonance (NMR)-based 
solution structure of the CAPERα RNA recognition motif 2 (RRM2) domain reported 
in Protein Data Base (PDB 2JRS) shows that 268glycine is located in the alpha-helix and 
directed outside the protein (Figure II-19). Combined, this structure model and my data 
suggest that 268glycine may be a part of degron of these sulfonamides and DCAF15 
protein complex. 
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A cell-growth-inhibition assay indicated that the G268V mutation in CAPERα 
confers resistance to the anti-proliferative activity of these sulfonamides in spite of 
strong growth inhibition by other cytotoxic agents (Figure II-20). Compared to 
sulfonamide-resistant HCT116 cells, K562-G268V cells were more sensitive to these 
sulfonamides, which might be due to heterozygous gene editing in K562 cells. In 
addition, siRNA-mediated CAPERα knockdown resulted in significant growth 
inhibition not only in the parental HCT116 cells but also in the resistant clonal cells 
(Figure II-21). All of these findings indicate that CAPERα has a critical biological 
function in HCT116 cell viability and the haploinsufficiency of HCT116 may render 
them particularly sensitive to E7820, indisulam, and CQS. 
CAPERα is an U2AF-related splicing factor (also designated RBM39, HCC1, 
FSAP59, and RNPC2) that serves as a coactivator for the transcription factors AP1, 
ERα, ERβ, ERRα, and NF-κB, and is involved in nuclear receptor-dependent 
alternative splicing32,34-38. It has previously been reported that RNAi-mediated 
knockdown of CAPERα changes the splice-form of vascular endothelial growth factor 
A (VEGF-A)35,36,38. Here, I confirmed the modulation of VEGF-A alternative splicing 
via the small-molecule-induced knockdown of the CAPERα protein in HCT116 cells 
using exon junction targeted qPCR. In particular, I observed a significant decrease in 
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VEGF-A-189 and a concomitant increase in VEGF-A-121 following treatment with 
these sulfonamides or CAPERα siRNA (Figure II-22). I also undertook a 
comprehensive comparison of the siRNA-based genetic perturbation of CAPERα and 
the small-molecule-based chemical perturbation of the protein using microarray-based 
transcriptomic analysis (Figure II-23a) and confirmatory qPCR analysis (Figure II-23b), 
which showed that there was a high correlation (r2 = 0.649) between the CAPERα 
siRNA (20 nM, 48 hours) and E7820 (1 µM, 24 h) treatments. In the qPCR assay, cells 
treated with these sulfonamides or siRNA exhibited changes in gene expression, with 
two genes upregulated (RBM15 and ZNF177) and four downregulated (ITGA2, 
SLC7A11, GSS, and CCNH) (Figure II-23b). 
 
 
Discussion 
In this study, I clarify that the anticancer action of the small molecule 
sulfonamides E7820, indisulam, and CQS is primarily driven by assembly of protein 
complex between CAPERα and DCAF15, which results in selective ubiquitination and 
degradation of CAPERα via CRL4DCAF15. The binding mode among the compound and 
proteins has yet to be fully elucidated, and in particular additional molecule(s), not 
identified in this study, might mediate the compound-proteins complex assembly. 
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However, this molecular mechanism would appear to closely resemble the 
lenalidomide-promoted CRBN-dependent destruction of IKZF1 and IKZF3, which 
results in anti-myeloma activity in the clinic. My finding, in addition to the 
lenalidomide story, suggests that the ubiquitin ligase system-targeted drug discovery 
and development may be expanded through the identification of different substrate 
protein targets to be coupled with specific DCAFs by small molecule like IMiDs and 
the present anticancer sulfonamides. Therefore, the structural basis of 
sulfonamide-induced degron recognition by CRL4DCAF15 should be clarified in future. In 
addition, CRL4DCAF15 might have other substrates which were not detected in my 
limited proteome datasets. Further investigations with these sulfonamides as selective 
chemical probes may extend my understanding of the biological functions of CAPERα, 
guiding us to the selection of right target cancer types with enhanced sensitivity to these 
drugs, e.g., cancers with aberrant splicing that is linked to malignant transformation of 
cells and disease progression39. 
Significantly, the putative mode of action of these sulfonamides, acting as a 
‘molecular glue’, raises an implication that DCAF-dependent, small molecule 
ligand-induced selective protein degradation might be originated in natural phenomenon 
which can be promoted by primary or secondary metabolites, as exemplified by the 
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plant hormone auxin (Figure II-1). Auxin connects SCFTIR1 ubiquitin ligase and 
Aux/IAA transcriptional repressors to regulate the growth and behavioral processes of 
plants40. Thus, my observation here might recapitulate a pharmacological example of 
processes that have already occurred in nature, suggesting new therapeutic possibilities 
through strategic chemical and pharmacologic intervention in such protein homeostasis 
pathways. 
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Materials and Methods 
Reagents.  
 E7820 (99.82% purity) and indisulam (E7070, 99.80% purity) were 
manufactured by Eisai Co. Ltd.; bortezomib, MLN4924, PR-619, and lenalidomide 
were purchased from LC Laboratories, Focus Biomolecules, Abcam, and BePharm Ltd., 
respectively; and doxorubicin and paclitaxel were purchased from Wako. All 
compounds were dissolved in DMSO. 
 
Cell culture.  
 HCT116 and MM.1S cells were obtained from the American Type Culture 
Collection (ATCC); and K562 cells were obtained from the Health Science Research 
Resources Bank (HSRRB). Cells were cultured in RPMI-1640 (Wako) supplemented 
with 10% fetal bovine serum (FBS; Sigma Aldrich) and 1% penicillin-streptomycin 
(Wako), and grown at 37 °C in a humidified incubator under 5% CO2. All cell lines had 
been authenticated by STR profiling, and confirmed mycoplasma free. Cells were 
treated with compounds dissolved in DMSO, and the equal amount of DMSO was 
added to control cells. DMSO concentrations were under 0.2%. 
 
Cell lysis and tryptic digestion for LC-MS/MS analysis. 
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 HCT116 or K562 cells were plated in 10-cm inner diameter (ID) dishes and 
cultured for 2 days before being treated with either DMSO or 3 µM of E7820 for 6 
hours. The HCT116 cells were washed twice with cold phosphate buffered saline (PBS, 
Wako), lysed using 7 M UREA (Wako), 2 M Thio-UREA (Wako), 3% 
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS, Pierce), 50 
mM NH4HCO3 (Wako), 50 mM dithiothreitol (DTT; Pierce or Calbiochem), and 
cOmplete(R) Protease Inhibitor Cocktail (Roche), and scraped onto the culture dish. 
The K562 cell cultures were collected and centrifuged to remove the supernatant, and 
the cells washed with cold PBS, centrifuged, and lysed using the same buffer as for the 
HCT116 cells. After removing cellular debris by centrifugation, the total protein 
contents were analyzed using Pierce 660 nm Protein Assay reagent.  
The protein alkylation and digestion procedure followed the Filter Aided Sample 
Preparation (FASP) method41, with some modification. Cell lysates of 100 µg protein 
were loaded on a Nanosep(R) 10K filter unit (PALL) and centrifuged at 12000 × g for 
20 min at rt. The protein samples on the filter unit were washed with an 8 M UREA/50 
mM NH4HCO3 solution, and carbamidomethylated with 50 mM of iodoacetamide for 
20 min at rt in the dark. The iodoacetamide solutions were then removed by 
centrifugation and the samples were washed with an 8 M UREA / 50 mM NH4HCO3 
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solution three times. The proteins were dissolved in a 5 M UREA / 50 mM NH4HCO3 
solution and then digested in the filter unit by 1 µg Lys-C (Wako) at 37 °C for 1 hour. 
The samples were then diluted four-fold with 50 mM NH4HCO3 solution to make 1 M 
UREA sample solutions, which were passed through a second digestion step using 1 µg 
sequencing grade trypsin (Promega) at 37 °C overnight. The digested samples were 
collected from the filter unit by centrifugation, following which the filters were washed 
twice with 8 M UREA. The samples were then acidified to make approximately 1% 
trifluoroacetic acid (TFA; Pierce) and desalted on an Empore solid phase extraction 
cartridge (C18 standard density, 3M). Peptides were eluted from the column with 80% 
acetonitrile/1% TFA, and then dried in a SpeedVac concentrator (Thermo Fisher 
Scientific).  
 
LC-MS/MS analysis.  
 Tryptic peptides from the whole cell lysate or immunoprecipitation samples 
were reconstituted in 5% methanol/0.1% TFA and analyzed in a nano-flow LC-MS/MS 
system using a Q Exactive™ HF mass spectrometer (Thermo Fisher Scientific) coupled 
with an online UltiMate(R) 3000 Rapid Separation LC (RSLC, Dionex) and an HTC 
PAL sample injector (CTC Analytics, Zwingen, Switzerland) fitted with a 
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microcapillary column (360 nm outer diameter (OD) × 100 µm ID), which was packed 
with < 20 cm of ReproSil C18-AQ 5 µm beads (Dr. Maisch GmbH) and equipped with 
an integrated electrospray emitter tip (P-2000 laser-based puller; Sutter Instruments). 
Each sample was loaded onto the capillary column by 4 µL full-loop mode injection. 
For LC separation, a mobile phase A of 4% acetonitrile/0.5% acetic acid (Wako) and a 
mobile phase B of 80% acetonitrile/0.5% acetic acid were used for multiple linear 
gradient elution from 1–37% of B over 60 min, 37–67% of B over 10 min, 67–99% of B 
over 5 min, and then held at 99% of B for 10 min, at 500 nL/min. The total analysis 
time for each sample was 120 min.  
Each sample was analyzed twice using two different acquisition modes of the Q 
Exactive HF mass spectrometer. The first of these was Data-Dependent Acquisition 
(DDA), which used higher energy collision dissociation (HCD) MS/MS scans 
(resolution 30,000) for the top 15 most abundant ions of each full-scan MS from m/z 
350 to 1500 (resolution 60,000) with a full-scan MS ion target of 3 × 106 ions and an 
MS/MS ion target of 2 × 105 ions. The maximum ion injection time for the MS/MS 
scans was 100 msec, the HCD normalized collision energy was set to 27, the dynamic 
exclusion time was set to 20 sec, and the peptide match and isotope exclusion functions 
were enabled. The second mode was Data-Independent Acquisition (DIA), which 
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consisted of 30 HCD MS/MS scans (resolution 30,000) with an isolation window of 27 
Da (25 Da step) to cover m/z 350 to 1100 and a full scan MS from 350 to 1100. This 
used a full scan MS ion target of 3 × 106 ions and an MS/MS ion target of 1 × 106 ions. 
The maximum ion injection time for the MS/MS scans and the HCD normalized 
collision energy were the same as for DDA.  
 
LC-MS data analysis.  
 All DDA mass spectra were analyzed with Proteome Discoverer ver. 1.4 
(Thermo Fisher Scientific) using a human Swiss-Prot database. Both MASCOT and 
SEQUEST-HT algorithms were used for MS/MS searching of the proteome datasets, 
with the following parameters: oxidation of methionine and protein N-terminal 
acetylation as variable modifications; carbamidomethylation of cysteine as a fixed 
modification; trypsin as the digestion enzyme; two missed cleavages per peptide were 
allowed; the mass tolerance for precursor ions was set to 10 ppm; and the mass 
tolerance for product ions was set to 20 mDa. A maximum false discovery rate (FDR) 
of 1% was applied for peptide identification. Protein identification required more than 
two peptides per protein without protein grouping.  
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 For the DIA dataset, peptide ion peak areas were extracted and integrated using 
Skyline software ver. 3.1.0.738242. Peptide spectral libraries were established based on 
Thermo’s MSF files using Proteome Discoverer ver. 1.4 with a cutoff score of 0.99. The 
target peptide was allowed to include the following structural modifications: oxidation 
of methionine and protein N-terminal acetylation as variable modifications; 
carbamidomethylation of cysteine as a fixed modification; and a maximum of two 
missed cleavages. Transitions were set with the following conditions: precursor 
charges-2, 3, 4; ion charges-1, 2; ion types-y, p; product ions-pick three product ions 
from the precursor m/z to the last ion, excluding the DIA precursor window; auto-select 
all matching transitions. Peak areas with a maximum of seven peptides per protein were 
extracted from the scans within 1 min of MS/MS identification. The product ion peak 
areas were then summed to yield the peptide peak area, which was used for statistical 
analysis. The log2 fold change in each peptide following E7820 treatment relative to the 
control value (DMSO treatment) was assessed using Welch’s t-test (p<0.05) in Excel 
2010 (Microsoft). 
 
Antibodies.  
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 The following antibodies were used: anti-CAPERα mouse monoclonal 
antibody (Santa Cruz Biotechnology, Inc, G-10; for immunoblot, 1:1000 dilution), 
anti-CAPERα rabbit polyclonal antibody (Bethyl Laboratories, A300-291A; for 
immunostaining and immunoprecipitation), anti-DCAF15 goat polyclonal antibody 
(Santa Cruz Biotechnology, Inc, N-16; 1:400 dilution), anti-DDB1 rabbit polyclonal 
antibody (Bethyl Laboratories, A300-462A; 1:2000 dilution), anti-ubiquitinylated 
proteins mouse monoclonal antibody FK2 (HRP conjugated, Enzo Life Sciences; 
1:1000 dilution), anti-Ikaros (IKZF1) rabbit polyclonal antibody (Cell signaling 
Technologies, #5443; 1:1000 dilution), anti-Aiolos (IKZF3) rabbit polyclonal antibody 
(Novus Biologicals, NBP2-24495; 1:1000 dilution), anti-GAPDH rabbit polyclonal 
antibody (Cell Signaling Technologies, 14C10; 1:2000 dilution), anti-vinculin mouse 
monoclonal antibody (Abcam, SPM227; 1:2000 dilution), normal rabbit IgG (Wako, 
148-09551; for immunoprecipitation), horse anti-mouse IgG HRP conjugated antibody 
(Cell signaling Technologies, #7076; 1:2000 dilution), goat anti-rabbit IgG HRP 
conjugated antibody (Cell Signaling Technologies, #7074; 1:2000 dilution), and donkey 
anti-goat IgG HRP conjugated antibody (Santa Cruz Biotechnology, Inc., sc-2020; 
1:4000 dilution). 
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Cell immunostaining.  
 The cells were washed with PBS and fixed in 2% paraformaldehyde (Wako) 
for 30 min. The cells were then rewashed with PBS, and permeabilized using 0.1% 
Triton X-100 for 30 min and blocked with Block Ace (DS Pharma Biomedical). The 
cells were incubated with anti-CAPERα antibody (1:2000 dilution; Bethyl Laboratories) 
and anti-SC-35 antibody (1:400 dilution; BD) overnight, washed with 0.05% tween20 / 
Tris-buffered saline (TBS), and then labeled with Cy5-conjugated anti-rabbit IgG 
antibody (Invitrogen), AlexaFluor488-conjugated anti-mouse IgG antibody (Invitrogen), 
and Hoechst 33342 (Sigma). Image acquisition was performed using CellVoyager6000 
(CV6000), which is an automated high-throughput cytological discovery system with 
laser-scanning confocal microscopes and image analysis software (Yokogawa Electric 
Corp., Tokyo, Japan). Three channels of excitation laser wavelengths were used (405, 
488, and 635 nm) and each well was scanned with a 40 × objective to produce an image. 
 
Immunoblot analysis.  
 The cells were washed with PBS and lysed with cold Pierce RIPA buffer 
(Thermo Fisher Scientific) containing the cOmplete(R) Protease Inhibitor Cocktail 
(Roche). After removing the cell debris by centrifugation, the total protein contents 
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were analyzed using the Pierce BCA assay. The extracts were reduced by DTT (Pierce) 
and separated on 4–20% SDS-polyacrylamide gradient gels (Biorad), following which 
the proteins were transferred to a nitrocellulose membrane (GE Healthcare Life 
Science) or PVDF (Biorad) membrane by electroblotting. After blocking with TBS 
(Takara) containing 5% non-fat dry milk (Wako) and 0.1% Tween-20 (Wako), the 
membrane was incubated with primary antibodies, followed by horseradish 
peroxide-conjugated secondary antibodies. Immunodetection was performed using 
Amersham ECL Prime (GE Healthcare Life Science), and a lumino-image analyzer 
(LAS-4000; GE Healthcare Life Science). 
 The DCAF15 immunoblot required some specific conditions. The cells were 
lysed with 4% SDS / 50 mM Tris-HCl (pH 7.5) containing the cOmplete(R) Protease 
Inhibitor Cocktail (Roche). After being reduced by DTT (Pierce), the protein samples 
were alkylated using iodoacetamide (Wako) to block non-specific binding by the 
antibody. The Biorad Trans-Blot(R) Turbo system was used for electroblotting. After 
blocking with TBS (Takara) containing 5% non-fat dry milk (Wako) and 0.1% 
Tween-20 (Wako), the membrane was incubated with the primary antibody 
anti-DCAF15 (N-16; Santacruz) in Canget Signal 1(R) (Toyobo Life Science 
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Department) at 4 °C overnight. Canget Signal 2(R) was also used for the second 
antibody incubation. 
 
Co-immunoprecipitation of CAPERα .  
 Cells were plated in 10-cm ID dishes at a density of 2 × 106 cells and incubated 
for 2 days. The cells were then pretreated with bortezomib for 30 min, following which 
E7820 or DMSO was added. After 3 hours’ incubation, the cells were washed twice 
with cold PBS and lysed with 0.25 M sucrose (Wako) / 0.3 mM sodium 
diethyldithiocarbamate trihydrate (Wako) / 1 mM CaCl2 (Wako) / 1 mM MgCl2 (Wako) 
/ 0.5 uM FeCl3 (Merck) / 0.1% PBS / 25 mM Tris-HCl (pH 7.5) (Nippongene) / 
cOmplete Protease Inhibitor Cocktail EDTA-free (Roche) lysis buffer in a culture dish. 
The cell lysates were collected and sonicated using an Astrason Ultrasonic Processor 
(MISONIX) and centrifuged at 12,000 × g for 20 min at 4 °C to remove any insoluble 
material. Protein A/G agarose beads (Pierce) and the anti-CAPERα antibody were 
incubated in lysis buffer at 4 °C, and then added to the cell lysates and incubated 
overnight at 4 °C in an end over end shaker. Following incubation, the samples were 
centrifuged at 2000 × g for 1 min at 4 °C to remove the supernatant, and the beads were 
then washed with sucrose buffer three times. The washed beads were extracted using 8 
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M UREA / 50 mM NH4HCO3 / 50 mM DTT solution followed by the FASP protocol 
described in the previous section. For immunoblotting, the beads were extracted using 
10% SDS/gel loading buffer (Biorad) / 50 mM DTT (Pierce). 
 
Cell-based ubiquitination assay.  
 DCAF15- or mock-vector-transfected DCAF15-/- HCT116 cells were plated in 
10-cm ID dishes at a density of 2 × 106 cells and incubated for 2 days. The cells were 
then pretreated with bortezomib for 30 min, following which PR-619 (30 µM) and 
either DMSO or E7820 (3 µM) were added. After 3 hours’ incubation, the cells were 
washed twice with cold PBS and lysed in 1 mL of cold Pierce RIPA buffer containing 
the cOmplete(R) Protease Inhibitor Cocktail and PR-619 (30 µM). The cell lysates were 
then sonicated in an ice-cold bath and frozen at −80 °C. The thawed cell lysates were 
again sonicated in an ice-cold bath and centrifuged at 12000 × g for 20 min at 4 °C to 
remove any insoluble material. Protein A/G agarose beads (Pierce) and anti-CAPERα 
antibody were incubated in 0.25 M sucrose-based buffer at 4 °C, and were then added to 
the cell lysates and incubated at 4 °C overnight in an end over end shaker. Following 
incubation, the beads were centrifuged at 2000 × g for 1 min at 4 °C to remove the 
supernatant, and were then washed with RIPA buffer containing protease inhibitor and 
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PR-619 three times. The washed beads were extracted using 10% SDS / gel loading 
buffer (Biorad) / 50 mM DTT (Pierce) for immunoblotting. 
 
3H-E7820 pulldown assay.  
 DCAF15- or mock-vector-transfected DCAF15-/- HCT116 cells were plated in 
10-cm ID dishes at a density of 2 × 106 cells per dish and incubated for 2 days. The cells 
were then pretreated with bortezomib for 30 min, following which 3H-E7820 (final 1 
µM) with or without cold E7820 (final 20 µM) were added. After 3 hours’ incubation, 
cell lysis and immunoprecipitation with the anti-CAPERα antibody were performed 
using the same method as described in the previous co-immunoprecipitation section. 
The washed beads were extracted by boiling them in 100 µL of sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer at 95 °C for 5 min. Half 
of each sample solution (50 µL) was diluted with 15 mL of Hionic-Fluor (PerkinElmer) 
and then analyzed twice using a liquid scintillation counter (PerkinElmer 
Tri-Carb2100TR). 
 
Photo-affinity labeling using the biotinyl photoactive E7820 probe.  
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 DCAF15-vector-transfected DCAF15-/- HCT116 cells were plated in 10-cm ID 
dishes at a density of 2.5 × 106 cells and incubated for 2 days. Following incubation, the 
cells were washed twice with cold PBS and lysed with 0.25 M sucrose / 0.3 mM sodium 
diethyldithiocarbamate trihydrate / 1 mM CaCl2 / 1mM MgCl2 / 0.5 uM FeCl3 / 0.1% 
PBS / 25 mM Tris-HCl (pH 7.5) / cOmplete(R) Protease Inhibitor Cocktail EDTA-free 
(Roche) lysis buffer in a culture dish. The cell lysates were collected and sonicated 
using an Astrason Ultrasonic Processor (MISONIX), and were then centrifuged at 
12,000 × g for 20 min at 4 °C to remove any insoluble material. The biotinyl 
photoactive E7820 probe (0.5 µM) was added to the cell lysates with a competitor 
(E7820, indisulam or CQS (30 M each), or DMSO) and then incubated for 30 min at 
4 °C in an end over end shaker. Following incubation, the samples were irradiated with 
ultraviolet (UV) light for 30 seconds using a 365-nm cut filter, and then 10% SDS 
solution (final about 1%) was added. Streptavidin beads that had previously been 
washed were added to the sample and incubated for 2 hours at rt in an end over end 
shaker. The streptavidin beads were then collected by centrifugation and washed with a 
0.5 % SDS / 50 mM Tris-HCl (pH 7.5) solution four times. The washed beads were 
extracted using 10% SDS/SDS-PAGE sample buffer / 50 mM DTT / 20 mM biotin for 
immunoblot analysis. 
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Quantitative RT-PCR.  
 TaqMan Gene Expression Assays (Life Technologies) used in this study are 
summarized in Supplementary Table 3. 
 For time course analysis of CAPERα gene expression and confirmation of 
siRNA-mediated knockdown, total RNA extraction and cDNA synthesis were 
performed using the Cell-to-CT™ kit (Ambion), according to the manufacturer’s 
protocol. A quantitative PCR analysis of the cDNA (total RNA equivalent) was carried 
out in duplicate (n = 3 biological replicates) using the TaqMan(R) Fast Advanced 
Master Mix (Life Technologies) on a ViiA7 Real-time PCR System (Life Technologies). 
Cycle threshold (Ct) values were determined using ViiA7 software version 1.1 (Life 
Technologies). The relative gene expression normalized against the expression level of 
GAPDH was calculated using Excel 2010 (Microsoft). 
 For analysis of the VEGFA splicing variant and a putative pharmacodynamic 
marker of CAPERα reduction, total RNA was prepared from HCT116 cells using 
RNeasy mini spin columns (Qiagen), according to the manufacturer’s protocol. The 
yield and quality of each isolated total RNA sample was determined using a 
NanoDrop(R) 1000 spectrophotometer (Thermo Fisher Scientific). The cDNA synthesis 
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was performed using a High Capacity cDNA Reverse Transcription Kit with RNase 
Inhibitor (Life Technologies), according to the manufacturer’s instructions. Quantitative 
PCR analysis of the cDNA (total RNA equivalent) was carried out in duplicate (n = 3 
biological replicates) using the TaqMan Gene Expression Master Mix (Life 
Technologies) on an ABI7900HT Real-time PCR System (Life Technologies). Cycle 
threshold (Ct) values were determined using SDS software version 2.2 (Life 
Technologies). A six-point standard curve was used to determine the PCR efficiency 
and relative quantitation. The relative gene expression normalized against the 
expression level of GAPDH was calculated using Excel 2010 (Microsoft). 
 
Reverse transfection of siRNA.  
 ON-TARGETplus siRNA and DharmaFECT 2 transfection reagent were 
obtained from GE Dharmacon. The siRNA used in this study are summarized in 
Supplementary Table 4. 
 For siRNA-mediated knockdown in HCT116 cells, 5 µL of DharmaFECT 2 
transfection reagent and 10 µL of 20 µM siRNA solution were mixed separately with 
375 µL Opti-MEM serum-free medium. After 5 min incubation at rt, these two solutions 
were mixed and incubated for more than 20 min at rt to generate a 
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siRNA/DharmaFECT complex. Following incubation, 15 µL or 375 µL aliquots of the 
siRNA/DharmaFECT complex were added into wells of a 96-well plate or 6-well plate, 
respectively. Trypsinized HCT116 cells in antibiotic-free medium were then added to 
each well to give a final concentration of 20 nM siRNA. The cells were incubated at 
37 °C in 5% CO2. 
 The knockdown efficacies of siRNA were assessed using qPCR or immunoblot 
analyses. J-011965-06 (RBM39), J-031237-18 (DCAF15), and J-012890-07 (DDB1) 
were then selected for further knockdown experiments. 
 
Plasmids for CRISPR/Cas9-based genome editing43,44.  
 The plasmid pC3-vector was constructed by deleting the SV40-Neo-pA 
module from the pcDNA3.1 vector (Thermo Fisher Scientific) using PCR-based 
mutagenesis (PrimeSTAR MAX DNA Polymerase; Clontech Laboratories Inc.). The 
DNA fragment coding hSpCas9-NLS was synthesized with codon-optimization by the 
GeneArt(R) gene synthesis service (Thermo), and fused with the DNA fragments that 
code the T2A peptide sequence and the green fluorescent protein hmAzamiGreen 
(Amalgaam Co., Ltd.). To construct the Cas9 expression plasmid 
pC3-hCas9N-2A-hmAG, hSpCas9-NLS and 2A-hmAzamiGreen were subcloned into 
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the pC3-vector. To guide RNA expression, the pMA-U6-BbsI vector was constructed. 
The DNA sequence of the U6 promoter-BbsI-sgRNA scaffold module was custom 
synthesized and subcloned into the pMA-vector by GeneArt service (Thermo). 
Oligonucleotides for the target sequence were synthesized, annealed, and subcloned into 
the BbsI site of the pMA-U6-BbsI vector.  
 
Plasmids for DCAF15 expression.  
 The piggyBac transposon vector pPBef1-mcs was constructed from the 
PB-EF1-MCS-IRES-GFP Vector PB530A-2 (System Biosciences Inc.) by removing 1.4 
kb of the EcoRI-SalI fragment, which codes IRES-copGFP. The DCAF15 open reading 
frame (ORF) (NCBI Reference Sequence: NM_138353) was synthesized by GeneScript. 
The IAG2AP module containing the IRES sequence followed by DNA encoding the 
hmAzamiGreen-T2A-Puromycin resistant gene was constructed using the In-Fusion 
method (Clontech). The EuRed ORF, which encodes the red fluorescence FusionRed 
protein (Evrogen) with codon modification, was synthesized by GeneArt service 
(Thermo). pPBef1-DCAF15-IAG2AP and the control plasmid PBef1-EuRed-IAG2AP 
were constructed by connecting each module using the In-Fusion method. 
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Transfection.  
 HCT116 or K562 cells were seeded at a density of 5.0 × 105 cells per well in a 
six-well plate before being transfected with plasmids using Lipofectamine(R) 3000 
reagent (Thermo) the following day. Approximately 250 µL of the transfection mixture 
contained 2.5–3.0 µg of plasmid DNA, 7.5 µL of Lipofectamine 3000, 5.0 µL of P3000 
solution, and 250 µL OptiMEM (Thermo). 
 For the knockout of DCAF15, 1.0 µg of the Cas9-plasmid and 1.0 µg of the 
sgRNA-plasmid (sgRNA sequence: CTCCAGCACATAGTACAGCTTGG, where the 
underlined 3-bp sequence is a Protospacer Adjacent Motif (PAM) sequence) were 
co-transfected into HCT116 cells. At 46 hours after transfection, the transfected cells 
were dissociated using Trypsin-EDTA solution (Wako) and mixed with the growth 
medium. The resuspended cells were filtered using a strainer cap tube and several 
hundred hmAzamiGreen positive cells were collected with a SONY SH800Z cell sorter. 
Following cell sorting, the transfected cells were treated and selected using 1 µM E7820, 
and were then cloned to establish DCAF15-/- HCT116 clonal cells. Knockout of the 
DCAF15 gene was confirmed by amplicon sequencing, as described below. 
For point-mutation introduction, 1.0 µg of the Cas9-plasmid, 1.0 µg of the 
sgRNA-plasmid (sgRNA sequence: TAACTGAAGATATGCTTCGTGGG, where the 
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underlined 3-bp sequence is a Protospacer Adjacent Motif (PAM) sequence), and 1.0 µg 
of antisense donor-ssDNA 
(GAAGATTCATTGAAGAACCTGGACTTACTCTTCCAAAAGGCTCAAAGATAA
CACGAAGCATATCTTCAGTTATGTTGAAGTGTAATGAGCCCACATAAA, 
where the underlined 3-bp sequence represents the G268V mutation site) were 
co-transfected into K562 cells. The transfected cells were treated and selected using 1 
µM E7820, and were then cloned to establish K562-G268V clonal cells. Introduction of 
the mutation was confirmed by amplicon sequencing for the genomic DNA (see below) 
and by immunoprecipitation/LC-MS/MS analysis for the protein. 
 For DCAF15 expression, following the transfection of HCT116 cells with 
DCAF15 and a mock vector using the piggyBac system with Lipofectamine 3000, the 
cells were treated and selected using 1 mg/mL puromycine. The expression of DCAF15 
was then confirmed by immunoblot analysis. 
 
Amplicon sequencing.  
 Genomic DNA was extracted using the PureLink(R) Genomic DNA Kit 
(Thermo), according to the manufacturer’s instructions. The genomic DNA was 
amplified with PrimeSTAR GXL DNA Polymerase (TaKaRa Bio.) with tailed primers 
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under the following conditions: 98 °C for 2 min; 35 cycles at 98 °C for 10 sec, 55 °C for 
15 sec, and 68 °C for 30 sec; and 68 °C for 5 min. A second PCR was then performed 
for indexing and adaptor addition for the Illumina platform. Here, 2 µL of PCR products 
were treated with 5 µL of ExoSAP-IT PCR Product Cleanup (USB/Affymetrix), diluted 
to 1:10, and used as a template. This PCR was performed using NEBNext(R) 
High-Fidelity 2X PCR Master Mix (New England Biolabs.) under the following 
conditions: 95 °C for 1 min; 30 cycles at 95 °C for 30 sec, 65 °C for 30 sec, and 72 °C 
for 3 min; and 72 °C for 5 min. The pooled samples were run on a 2% E-Gel(R) EX 
Agarose Gel (Thermo) and the correct fragments were gel extracted with the 
NucleoSpin(R) Gel and PCR Cleanup Kit (MACHEREY-NAGEL GmbH). Purified 
libraries were quantified with the QuantiFluor dsDNA System (Promega) and run on an 
Illumina MiSeq (Illumina Inc.).  
 The MiSeq sequencing run generated Illumina FASTQ files. These files were 
processed using in-house tools to convert the file format. Data analysis such as 
sequence filtering, counting reads, and visualization were performed using the TIBCO 
Spotfire software. The primers used in the amplicon sequencing and indexing are 
summarized in Supplementary Table 5, 6. 
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Exome sequencing.  
 Genomic DNA of parental HCT116 and resistant clonal HCT116 cells were 
extracted and enriched using the DNeasy Blood & Tissue Kit (Qiagen) and SureSelect 
Human All Exon V5 (Agilent), according to the manufacturer’s protocol. Whole exome 
sequencing was performed using a HiSeq 2000 (Illumina) with 100 base pairs on each 
end. The read numbers for the parental HCT116 cell line and resistant clone were 78.4 
million and 94.1 million, respectively. 
 The reads were aligned to the reference genome sequence (GRCh37) using the 
Burrows-Wheeler Aligner (BWA)45. The Genome Analysis Toolkit (GATK) was used 
for base quality score recalibration, indel realignment, and duplicate removal46. To 
extract drug-resistance-associated mutations, three ﬁlters were applied to all locations 
on the target genome regions with mpileup base frequencies of A, T, G, and C. The ﬁrst 
ﬁlter was a chi-squared test, which can be used to distinguish differences in base 
frequencies between sulfonamide-resistant and parental HCT116 cells; the cutoff value 
for this was set at 0.001. The second filter was a depth ﬁlter, whereby the depth of 
sequence coverage needed to be ﬁve or more for both samples. The ﬁnal ﬁlter was a 
non-synonymous single nucleotide polymorphism ﬁlter, which focused on the 
functional changes caused by the mutations. 
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Sanger sequencing.  
 The CAPERα fragment was amplified from genomic DNA using PCR primers 
flanking the R87* and G268V mutations. The PCR products were treated with 
Exo-SAP-IT (USB/Affymetrix) and sequenced directly with PCR primers. Cycle 
sequencing was performed using a BigDye Terminator kit, version 3.1 (Applied 
Biosystems). The products of the sequencing reactions were purified using a Performa 
DTR Ultra 96-Well Plate Kit (Edge BioSystems) and sequenced in a 16-capillary ABI 
PRISM 3130xl Genetic Analyzer (Applied Biosystems). 
 
Transcriptional comparison using DNA microarray.  
 HCT116 cells were seeded in a six-well plate at a density of 1.0 × 105 cells per 
well with or without the siRNA reverse transfection of the siGENOME SMARTpool of 
RBM39 (Dharmacon, M-011965) and non-targeting siRNA pool #2 (D-001206-14). 
Following incubation overnight, DMSO or E7820 were added to the siRNA-free 
HCT116 plate (final 1 µM of E7820) and incubated for 24 hours. Cells were then 
harvested using 350 µL of Buffer RLT (Qiagen) containing 1% 2-mercaptethanol 
(Nakalai tesque) either 48 hours after treatment with the siRNA or 24 hours after 
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treatment with the compounds, and stored at −80 °C until the next step. All sample 
groups were prepared with three biological replicates. 
 Total RNA was prepared using RNeasy mini spin columns (Qiagen), according 
to the manufacturer’s protocol. The yield and quality of each isolated total RNA sample 
was determined using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific) 
and an RNA Nano LabChip(R) kit analyzed on a 2100 Bioanalyzer (Agilent 
Technologies). NanoDrop spectrophotometers measure the absorbency at wavelengths 
of 280 nm and 260 nm, the ratios of which (i.e., A260:A280) are then used to assess 
sample purity; an A260:A280 ratio of approximately 2.0 is considered pure for RNA 
samples. By contrast, the 2100 Bioanalyzer calculates an RNA Integrity Number (RIN) 
based on the pattern of total RNA electrophoresed, which can be used as a metric for 
RNA degradation (Schroeder et al., 2006); a RIN of 9.7–10.0 is considered pure for 
total RNA from hiPSC-derived cardiomyocytes. 
 Total RNA (200 ng) was converted to cyanine-3 (Cy3)-labeled complementary 
RNA (cRNA) using a Low Input Quick Amp Labeling Kit, One-Color (Agilent 
Technologies), according to the manufacturer’s instructions for single-color 8×60K 
gene expression arrays. Cy3-labeled cRNAs were purified using an RNeasy Mini 
purification kit (Qiagen) and hybridized to the SurePrint G3 Human Gene Expression 
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8×60K Microarray (Agilent Technologies) at 65 °C for 17 hours with a Gene 
Expression Hybridization Kit (Agilent Technologies), according to the manufacturer’s 
instructions. The arrays were washed with a Gene Expression Wash Pack (Agilent 
Technologies) and scanned on a DNA Microarray Scanner (Agilent Technologies), 
according to the manufacturer’s instructions. The scanned images were then quantified 
using Feature Extraction software (version 11.5.1.1, Agilent Technologies), and the 
resulting files were imported and analyzed with GeneSpring (version 12.5, Agilent 
Technologies). The raw data were normalized using a quantile method. The differences 
between treatments were assessed using Welch’s t-test, followed by an adjustment for 
multiple comparisons using the FDR approach (Benjamini-Hochberg procedure). A 
gene was considered to be differentially expressed when its absolute fold change 
relative to the control value was ≥ 1.5 with an FDR P-value of ≤ 0.05. 
 
Computational amino acid substitution of CAPERα .  
 268Glycine in the CAPERα NMR structure PDB:2JRS was mutated to Valine 
and the side chain of the mutated Valine was energy minimized using CHARMm force 
field. Modeling and minimization was carried out using Discovery Studio 3.5 (Dassault 
Systemes, www.3ds.com). 
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Cell viability assay. 
 Cells were plated in a 96-well microtiter plates with or without siRNA reverse 
transfection and incubated overnight. Serial dilutions of compounds were then added to 
each well. After 3 days, 10 µL of WST-8 reagent (Dojindo) was added to each well. The 
absorbency at 450 nm (A450) was monitored and compared with a reference 
measurement at A660 using an EnVision 2103 Multilabel Reader (PerkinElmer), 
RAINBOW microplate reader (SLT Lab Instruments), or Sunrise microplate reader 
(TECAN). 
 
Chemistry. 
General chemistry procedures; 
 1H NMR spectra and 13C NMR spectra were recorded on a Varian Mercury 400 
spectrometer (operating at 400 MHz) and a Bruker Avance 600 (operating at 150 MHz), 
respectively. Chemical shifts were calculated in ppm (δ) from the residual CH3OH 
signal at δH = 3.31 ppm and δC = 49.0 ppm, or the DMSO signal at δH = 2.50 ppm and 
δC = 39.7 ppm. 1H NMR data were processed using an ACD/Spectrus Processor from 
ACD Laboratories. Ultra performance liquid chromatography (UPLC) analyses were 
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performed using an ACQUITY UPLC system. Column chromatography was carried out 
using a Hi-Flash column (40 µm, silica gel and NH-silica gel, Yamazen Corporation). 
Purification and analysis of 3H-E7820 was carried out using HPLC with Gemini C18 
column (phenomenex). All chemicals and solvents were purchased from commercial 
suppliers. 
 
Synthesis of chloroquinoxaline sulfonamide (CQS); 
  
 2,5-dichloroquinoxaline47 (6, 500 mg, 2.51 mmol), 
4-aminobenzene-1-sulfonamide (7, 476 mg, 2.76 mmol), and K2CO3 (694 mg, 5.02 
mmol) were dissolved in dimethylformamide (DMF) (5 ml). This solution was then 
stirred at 150 °C for 3 hours, following which the reaction was poured into water (5 mL) 
and filtered. The filtrate was acidified to pH 4 by adding aqueous HCl, resulting in the 
precipitation of a yellow solid. The filter cake was dried in vacuo and the residue was 
purified by column chromatography (petroleum ether / ethyl acetate. 5:1) to give CQS 
(3, 244 mg, 0.730 mmol, 29% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6): 
δ ppm = 6.07 (brs, 2H), 6.43–6.70 (m, 2H), 7.55–7.91 (m, 5H), 8.59 (s, 1H), 11.72 (brs, 
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1H). 13C NMR (150 MHz, DMSO-d6): δ ppm = 112.4, 123.7, 126.7, 127.3, 130.4, 
130.9, 132.1, 134.7, 139.0, 141.3, 147.0, 153.7. LC-MS: m/z = 335 [M+H], 333 [M-H]. 
 
Preparation of tritium-labeled E7820; 
 
 3-Bromo-5-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide; 
3-Bromo-5-cyanobenzene-1-sulfonylchloride (8, 0.30 g, 1.1 mmol), 
7-amino-3-cyano-4- methylindole (9, 0.17 g, 0.98 mmol)48, and 
4-dimethyaminopyridine (0.28 g, 0.25 mmol) were dissolved in 2 mL of pyridine, and 
the solution was stirred at room temperature (rt) for 5 hours. The solution was then 
diluted with ethyl acetate (AcOEt), and washed with 0.1 N HCl followed by brine, dried 
over MgSO4, and evaporated to provide a slightly colored solid. This was then filtrated 
and washed with MeOH to provide the product (10, 0.30 g, 0.72 mmol, 82% yield). 
1H-NMR (400 MHz, DMSO-d6): δ ppm = 12.12 (brs, 1H), 10.21 (brs, 1H), 8.49 (s, 1H), 
8.21 (s, 1H), 8.08 (s, 1H), 8.04 (s, 1H), 6.84 (d, J = 7.6 Hz, 1H), 6.53 (d, J = 7.6 Hz, 
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1H), 2.60 (s, 3H). 13C NMR (150 MHz, DMSO-d6): δ ppm = 17.9, 84.6, 114.5, 116.3, 
117.4, 119.4, 120.2, 122.7, 123.0, 126.9, 129.0, 129.7, 131.7, 133.9, 135.7, 139.2, 142.1. 
LC-MS: m/z = 415, 417 [M+H]. 
 
3-Cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)-[5-3H]-benzenesulfonamide; 
 3-Bromo-5-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide (5 
mg, 12 µmol) and 10% Pd-C (10 mg) were added to in the solution of 1 mL of DMF 
and 10 µL of N,N-diisopropylethylamine. The mixture was stirred under tritium gas 
(111 GBq) for 2 hours. The mixture was then diluted with EtOH and the catalyst was 
removed by filtration. The crude product was purified by high-performance liquid 
chromatography (HPLC) (25 × 0.96 cm Ultrasphere ODS column in an 
H2O/MeCN/TFA system) using 
3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide as a reference. The 
purified fraction was evaporated to dryness and dissolved in EtOH as a 189 MBq/mL 
solution. MS: m/z = 337, 339 [M+H]. Radiochemical purity: 99.7% by HPLC. 
Specific activity: 629 GBq/mmol. 
 
Preparation of the biotinyl photoactive E7820 probe; 
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 The validity of using linker substitution in a sulfonamide compound has been 
described previously49. 
 
 7-amino-4-methyl-1H-indole-3-carbonitrile (11, 300 mg, 1.76 mmol) was 
dissolved in 5 ml of tetrahydrofuran (THF) at 0 °C. Pyridine (0.356 ml, 4.40 mmol) was 
then added to the solution. After 10 min, 4-(bromomethyl)benzene-1-sulfonylchloride 
(12, 712 mg, 2.64 mmol) in 5 ml of THF was added to the reaction mixture and the 
mixture was stirred at rt overnight. The reaction mixture was then diluted with EtOAc 
(30 ml) and poured onto a sat. aq. NH4Cl solution (50 ml). The organic phase was 
separated from the aqueous solution, washed with brine (50 ml), and dried over MgSO4 
and filtered. The organic phase was then evaporated to yield the crude product. Silica 
gel chromatography eluting with 30–100% EtOAc-heptane provided a mixture of 
4-(bromomethyl)-N-(3-cyano-4-methyl-1H-indol-7-yl)benzene-1-sulfonamide (13), 
which was used in the next step without further purification. 
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The obtained product (13, 712 mg) was dissolved in DMF (14.6 ml). Sodium 
azide (572 mg, 8.81 mmol) was then added to the solution, which was stirred overnight 
at rt. The mixture was poured into water and extracted with ethyl acetate/diethyl ether 
(EtOAc/Et2O, 1:1). The organic phase was separated from the aqueous solution and 
washed with brine, dried over MgSO4, and concentrated under reduced pressure. The 
crude product was then purified by silica gel column chromatography (20–60% EtOAc 
in heptane) to provide 
4-(azidomethyl)-N-(3-cyano-4-methyl-1H-indol-7-yl)benzene-1-sulfonamide (14, 89.5 
mg, 13.9% yield). 1H NMR (400 MHz, DMSO-d6): δ ppm = 2.56 (s, 3H), 4.56 (s, 2H), 
6.53 (d, J = 7.6 Hz, 1H), 6.75 (d, J = 1 Hz, 7.6 Hz, 1H), 7.50 (d, J = 7.2 Hz, 2H), 7.71 
(brd, J = 7.2 Hz, 2H), 8.16 (s, 1H), 9.95 (brs, 1H), 11.53 (brs, 1H). 13C NMR (150 MHz, 
DMSO-d6): δ ppm = 17.8, 52.9, 84.5, 117.5, 118.8, 120.5, 122.5, 126.7, 127.5, 127.8, 
128.9, 131.0, 135.4, 138.8, 141.0. LC-MS: m/z = 367 [M+H], 389 [M+Na]. 
4-(Azidomethyl)-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide (500 
mg, 1.365 mmol) was dissolved in THF/water (10:1). Triphenylphosphine (537 mg, 
2.047 mmol) was then added to the solution and the reaction mixture was stirred at 
60 °C for 8 hours. The mixture was concentrated under reduced pressure and the 
precipitated white solid was collected by paper filtration. The solid was washed with 
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CH2Cl2 and dried in vacuo to obtain 
4-(aminomethyl)-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide (15, 388 mg, 
1.140 mmol, 84% yield). 1H NMR (400 MHz, DMSO-d6): δ ppm = 3.17 (s, 2H), 3.84 
(s, 3H), 6.64 (s, 2H), 7.42 (d, J = 8.06 Hz, 3H), 7.68 (d, J = 8.25 Hz, 3H), 8.00 (s, 1H). 
13C NMR (150 MHz, DMSO-d6): δ ppm = 17.7, 44.0, 83.9, 115.4, 118.1, 122.7, 123.0, 
126.1, 126.6, 126.8, 127.9, 130.7, 134.2, 141.3, 144.0. LC-MS: m/z = 341 [M+H]. 
 
 
 4-(Aminomethyl)-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide 
(15, 4.26 mg, 0.013 mmol), triethylamine (4.75µl, 0.034mmol) and sodium  
1-({3-[(2-{[2-(4-azidobenzamido)-6-{[5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanoyl]amino}hexanoyl]amino}ethyl)disulfanyl]propanoyl}oxy)-2,5-dioxopyrroli
dine-3-sulfonate (16, 10 mg, 0.011 mmol) (Thermo Fisher Scientific, #33033) were 
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dissolved in DMF (1 ml) and stirred overnight at rt. The reaction mixture was then 
concentrated under reduced pressure and the obtained residue was purified by silica gel 
flash chromatography (10–20% methanol in ethylacetate) to provide the target biotinyl 
photoactive chemical probe, 
4-azido-N-[1-{4-[(3-cyano-4-methyl-1H-indol-7-yl)sulfamoyl]phenyl}-3,11,18-trioxo-2
2-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-6,7-dithia-2,10,17-triazadocosan-12
-yl]benzamide (5, 10.4 mg, 10.37 µmol, 91% yield). 1H NMR (400 MHz, 
METHANOL-d4): δ ppm = 1.36–1.92 (m, 12H), 2.15 (t, J = 7.06 Hz, 2H), 2.62 (s, 3H), 
2.62–2.3 (m, 4H), 2.83 (t, J = 6.78 Hz, 2H), 2.97 (t, J = 6.78 Hz, 2H), 3.12–3.20 (m, 
2H), 3.42–3.59 (m, 3H), 4.26 (dt, J = 7.70, 3.85 Hz, 1H), 4.40 (s, 2H), 4.42–4.51 (m, 
2H), 4.62 (brs, 1H), 6.47 (d, J = 7.70 Hz, 1H), 6.71 (d, J = 7.51 Hz, 1H), 7.09 (d, J = 
8.25 Hz, 2H), 7.37 (d, J = 8.25 Hz, 2H), 7.59 (d, J = 8.25 Hz, 2H), 7.82–7.94 (m, 3H). 
13C NMR (150 MHz, DMSO-d6): δ ppm = 18.3, 24.5, 26.9, 29.4, 29.7, 30.1, 32.7, 35.3, 
36.5, 36.8, 38.5, 39.6, 40.0, 41.0, 43.6, 55.6, 57.0, 62.3, 63.4, 86.1, 118.6, 119.9, 121.5, 
121.8, 123.8, 128.3, 128.7, 128.9, 130.1, 130.5, 131.6, 133.2, 135.5, 139.2, 145.1, 145.6, 
166.1, 169.2, 173.8, 174.7, 176.1. LC-MS: m/z = 1003 [M+H]. 
 
Data availability. 
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Proteome, exome sequencing, and DNA microarray data have been deposited in the 
jPOST (accession code: JPST000232), NCBI (accession code: SRP097451), and GEO 
(accession code: GSE93829), respectively. 
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Figures 
Figure II-1. Chemical structures of the anticancer sulfonamides E7820 (1), 
indisulam (2), and CQS (3), immunomodulatory drugs (IMiDs) lenalidomide and 
thalidomide, auxin, 3H-E7820 (4), and the biotynyl photoactive E7820 probe (5). 
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Figure II-2. Cell viability assay results for the parental HCT116 human colorectal 
cancer cell line and a spontaneously occurring indisulam-resistant subclonal cell 
line. Cells were treated with E7820, indisulam, and chloroquinoxaline sulfonamide 
(CQS), and the cytotoxic agents doxorubicin and paclitaxel. Data are presented as the 
mean of three independent experiments ± SD. 
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Figure II-3. Down-regulation of CAPERα  by E7820, indisulam, and CQS.  (a) Proteome-wide 
analysis of HCT116 and K562 cells treated with 3 µM E7820 or DMSO for 6 hours. Each point 
represents the log2 ratio of mean tryptic peptide ion peaks in E7820- versus DMSO-treated cells (n = 
3, P < 0.05). (b) In vitro cell staining of HCT116 cells treated with 3 µM E7820 or DMSO for 22 
hours. Scale bars, 50 µm. (c) Immunoblot analysis of HCT116 and K562 cells treated with the 
indicated concentrations of E7820, indisulam, CQS, or DMSO for 24 hours. (d) Time course of 
CAPERα protein levels and (E) mRNA levels in HCT116 and K562 cells treated with 3 µM E7820 
or DMSO. Immunoblot results are representative of two independent experiments. qPCR data are 
presented as the mean ± SD (n = 3). 
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Figure II-4. E7820, indisulam, and CQS promote CRL4DCAF15 mediated CAPERα  
degradation. (a) Chemical rescue of CAPERα degradation in HCT116 and K562 cells 
treated with 3 µM E7820 or DMSO for 6 hours. Cells were pretreated with MLN4924 
(1 µM) or bortezomib (0.2 µM) before the addition of E7820. (b) CAPERα interaction 
analysis of HCT116 and K562 cells treated with E7820 (1 µM) or DMSO for 6 hours. 
Each point represents the log2 ratio of the mean tryptic peptide ion peak following 
CAPERα co-immunoprecipitation in E7820- versus DMSO-treated cells (n = 3, P < 
0.05).  
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Figure II-5. siRNA-mediated knockdown of DCAF15 and DDB1 in HCT116 cells. 
(a) Reductions in mRNA expression by siDCAF15 and siDDB1 were assessed using 
quantitative polymerase chain reaction (qPCR). Cells were transfected with siRNA and 
incubated for 2 days. Data are presented as mean ± SD (n = 3). (b) Effect of 
sulfonamides on CAPERα in siRNA-transfected cells. Cells were transfected with 
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siRNA and incubated for 2 days, and then treated with E7820 (3 µM), indisulam (3 µM), 
CQS (30 µM), or DMSO for 6 hours. (c) Viability of HCT116 cells with 
siRNA-mediated knockdown of DCAF15 or DDB1. Cell viabilities were normalized 
with the viability of non-target siRNA treated cell. Data are presented as mean ± SD (n 
= 3). (d) Cell viability of HCT116 cells with siRNA mediated gene knockdown and 
sulfonamide treatment. Cell viabilities were normalized with the viabilities of DMSO 
control cells in each siRNA treatment group. Data are presented as mean ± SD (n = 3). 
Cells were transfected with siRNA and incubated for 1 day, and then treated with E7820 
(3 µM), indisulam (3 µM), CQS (30 µM), or DMSO for 72 hours. 
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a 
Wild Type 
CGCTCACCATCCTCCGGCTCCGTCCCCTCTCCGGACTCCAGC 
ACATAGTACAGCTTGGTGTAGTTGACATAGCCAGGCTCGGA 
GGCAGGTGCCTCCGAGG 
Insertion-A 
CGCTCACCATCCTCCGGCTCCGTCCCCTCTCCGGACTCCAGC 
ACATAGTACAAGCTTGGTGTAGTTGACATAGCCAGGCTCGGA 
GGCAGGTGCCTCCGAG 
Insertion-T 
CGCTCACCATCCTCCGGCTCCGTCCCCTCTCCGGACTCCAGC 
ACATAGTACTAGCTTGGTGTAGTTGACATAGCCAGGCTCGGA 
GGCAGGTGCCTCCGAG 
 
b 
 Gene Sequencing of DCAF15 HCT116 Parent 
HCT116 
DCAF15-/- 
Total Lead Number 55679 70183 
Relative Lead 
Number (%) 
Wild Type 100 0 
Insertion-A 0 49.86 
Insertion-T 0 45.47 
Others 0 4.67 
 
 
 
Figure II-6. CRISPR/Cas9-based DCAF15 knockout in HCT116 cells. (a) Gene 
sequences of the wild type and the line exhibiting a single nucleotide insertion of 
DCAF15 by CRISPR/Cas9. (b) DCAF15 allele ratio in parental HCT116 and its 
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DCAF15 knockout clonal cells analyzed by amplicon sequencing. Short reads (< 100 bp 
long) and minor reads (< 1% frequency) were excluded from the analysis. 
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Figure II-7. Immunoblot analysis of parental and DCAF15 knockout clones of 
HCT116 cells. Cells were treated with E7820 (3 µM), indisulam (3 µM), CQS (30 µM), 
or DMSO for 6 hours. 
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Figure II-8. Growth inhibitory curves of anticancer sulfonamides and cytotoxic 
agents in parental and DCAF15-/- HCT116 cells. Data are presented as the mean ± 
SD (n = 3).  
 
  
62 
 
 
Figure II-9. siRNA-mediated knockdown of CUL4A and CUL4B in HCT116 cells. 
Effect of sulfonamides on CAPERα in siRNA-transfected cells. Cells were transfected 
with siRNA and incubated for 2 days, and then treated with E7820 (3 µM), indisulam (3 
µM), CQS (30 µM), or DMSO for 6 hours. 
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Figure II-10. DCAF15 is the primary target of E7820, indisulam, and CQS in the 
ubiquitination of CAPERα . (a) Effect of sulfonamides on CAPERα in DCAF15 and 
mock-vector-transfected DCAF15-/- HCT116 cells treated with 3 µM E7820 or DMSO 
for 6 hours. (b) Immunoprecipitation and immunoblot analysis of the CAPERα binding 
protein. Cells were pretreated with bortezomib (0.5 µM) before treatment with E7820 (3 
µM) or DMSO for 3 hours. IP, immunoprecipitation with anti-CAPERα antibody. (c) 
Cell-based ubiquitination analysis of endogenous CAPERα. Cells were pretreated with 
bortezomib (0.5 µM) before treatment with E7820 (3 µM) or DMSO, and the 
de-ubiquitination inhibitor PR-619 (30 µM), as indicated, for 3 hours. IP, 
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immunoprecipitation with anti-CAPERα antibody. (d) 3H-E7820 pulldown by 
CAPERα immunoprecipitation. Cells were pretreated with bortezomib (0.5 µM), and 
then treated with 3H-E7820 (1 µM) for 3 hours with or without cold E7820 competition 
(20 µM). Data are the mean of two cycle analyses. (e) Photoaffinity labeling of target 
protein with the biotinylated photoactive E7820 probe. The DCAF15-vector-transfected 
DCAF15-/- HCT116 cell lysate with or without competition of the sulfonamide 
derivatives (30 µM) that had been incubated with the E7820 probe for 30 min followed 
by UV irradiation. Labeled proteins were enriched using streptavidin beads followed by 
immunoblot analysis.  
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Figure II-11. Degradation of CAPERα , IKZF1, and IKZF3 in MM.1S cells. 
Immunoblot analyses of MM.1S cells treated with DMSO, E7820 (3 or 30 µM), or 
lenalidomide (1 or 10 µM) for 12 hours.  
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b 
 
 
Figure II-12. Discovery of the CAPERα  mutations in parental HCT116 and 
spontaneously generated sulfonamide-resistant clonal cells. (a) Mapping of the 
CAPERα mutation in sulfonamide-resistant HCT116 cells. (b) Sanger sequencing of 
G268V missense mutation and (c) R87-nonsense mutation in the parental HCT116 and 
sulfonamide-resistant clonal cells. 
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Figure II-13. Immunoprecipitation-LC-MS/MS analysis of CAPERα  in the 
parental HCT116 cells and spontaneously appearing sulfonamide-resistant clonal 
cells. (a) Mass chromatograms of the wild type and mutant peptides from trypsinized 
CAPERα. Results are representative of two independent experiments. (b) MS/MS 
spectra of the wild type and mutant peptides from trypsinized CAPERα. 
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Figure II-14. Immunoblot analysis of parental and sulfonamide-resistant HCT116 
cells. Cells were treated with E7820 (3 µM), indisulam (3 µM), CQS (30 µM), or 
DMSO for 6 hours. Results are representative of two independent experiments. 
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Figure II-15. Co-immunoprecipitation/liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) analysis of CAPERα . Parental HCT116 or 
sulfonamide-resistant clonal cells were treated with either E7820 or DMSO for 3 hours. 
Data are presented as the mean of the LC-MS/MS peak areas ± SD (n = 3). 
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a	
Wild Type 
GGCTTTATGTGGGCTCATTACACTTCAACATAAC 
TGAAGATATGCTTCGTGGGATCTTTGAGCCTTTT 
GGAAGAGTAAGTCCAGGTTCTTCAATGAATCTT 
CAGTAGGTTGTTGATCTGAGTATAACTACAT 
G268V-CRISPR 
GGCTTTATGTGGGCTCATTACACTTCAACATAAC 
TGAAGATATGCTTCGTGTTATCTTTGAGCCTTTT 
GGAAGAGTAAGTCCAGGTTCTTCAATGAATCTT 
CAGTAGGTTGTTGATCTGAGTATAACTACAT 
 
b	
CAPER/RBM39 Sequencing Bulk E7820 selected G268V clone 
Total Lead Number 476225 392541 158846 
Relative Lead 
Number (%) 
Wild Type 97.4 15.4 62.7 
G268V 1.2 66.5 37.3 
Others 1.5 18.1 0.0 
 
 
 
Figure II-16. Biological confirmation of the mutation-based resistance of CAPERα . 
(a) Gene sequences of the wild type and edited G268V CAPERα. (b) CAPERα 
amplicon sequencing of bulk K562 cells with transfection of the CRISPR/Cas9 system, 
following enrichment by E7820 treatment, and a clonal cell obtained from 
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E7820-treated cells. Short reads (< 100 bp long) and minor reads (< 1% frequency) 
were excluded from the analysis. 
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Figure II-17. Immunoblot analysis of parental and mutant K562 cells. Cells were 
treated with E7820 (3 µM), indisulam (3 µM), CQS (30 µM), or DMSO for 6 hours.  
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Figure II-18. Immunoprecipitation/LC-MS/MS analysis of CAPERα  from 
K562-G278V cells. Cells were treated with (a) DMSO or (b) E7820 (3 µM) for 6 hours. 
Each chart shows a high-resolution mass chromatogram of the wild type and mutant 
CAPERα tryptic peptide from K562-G278V cells. 
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Figure II-19. NMR-based solution structure of CAPERα  RNA recognition motif 2 
(RRM2, PDB 2JRS), showing the substitution of 268Glycine to Valine (ball and 
stick). 
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Figure II-20. Growth inhibitory activity of the anticancer sulfonamides and 
cytotoxic agents against parental K562 or K562-G268V cells. Data are presented as 
the mean of three independent experiments ± SD. 
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Figure II-21. Utilization of siRNA-mediated knockdown of CAPERα in HCT116 
cells. (a) Effects of the knockdown of CAPERα mRNA assessed using quantitative 
polymerase chain reaction (qPCR) 48 hours after treatment with siRNA. Data are 
presented as mean ± SD (n = 3). (b) The reduction in CAPERα protein expression 
assessed by immunoblot 48 hours after treatment with siRNA. (c) The effect of 
siRNA-mediated CAPERα knockdown on parental or sulfonamide-resistant HCT116 
cells. Data are presented as the mean ± SD (n = 3). 
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Figure II-22. Comparison of mRNA splicing modulation between the 
E7820-induced degradation and siRNA-mediated knockdown of CAPERα . (a) 
Correspondence between the exon-exon junctions and the splicing variants of VEGF-A. 
The PCR primers of exon junctions exon-5/6, exon-5/7, exon-5/8, and exon-2 
correspond with the splicing variants VEGF-A-189, VEGF-A-165, VEGF-A-121, and 
total VEGF-A, respectively. (b) Exon junction targeted qPCR of VEGF-A in 
sulfonamide- or siRNA-treated HCT116 cells. Cells were treated with E7820 (3 µM), 
indisulam (3 µM), CQS (30 µM) or DMSO for 24 hours, or siRNA for 48 hours. Data 
are presented as the mean ± SD (n = 3). 
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Figure II-23. Transcriptional comparison between the E7820-induced degradation 
and siRNA-mediated knockdown of CAPERα . (a) Cells were incubated with E7820 
(1 µM) or DMSO for 24 hours, or siRNA for 48 hours to be analyzed by DNA 
microarray. Each point represents the log2 ratio of gene expression. Data are presented 
as the mean of biologically triplicate analyses, P < 0.05. (b) Gene expression of putative 
pharmacodynamic markers were assessed using quantitative polymerase chain reaction 
(qPCR). Cells were incubated with E7820 (3 µM), indisulam (3 µM), CQS (30µM), or 
79 
 
dimethyl sulfoxide (DMSO) for 24 hours, or siRNA for 48 hours. RNA levels of 
compounds and siCAPER treated cells were normalized with the RNA levels of DMSO 
control and non-target siRNA treated cells, respectively. The data are presented as mean 
± SD (n = 3). 
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Tables 
Table 1. Growth inhibitory activity of sulfonamide derivatives in HCT116 and 
K562 cells. The data are presented as the mean of three independent assays ± SD. 
 
 Mean IC50 (µM) SD (±) 
HCT116 
E7820 0.08 0.02 
Indisulam 0.18 0.02 
CQS 4.9 1.13 
K562 
E7820 0.54 0.15 
Indisulam 0.94 0.08 
CQS 20.55 2.49 
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Table 2. Summary of differential exome sequencing between parental HCT116 
cells and spontaneously appearing sulfonamide-resistant clonal cells. 
 
 
  
Gene Chromosome Position Functions
Amino Acid
Changes
Codon
Change
Total
Depth
Alteration
Frequency
(%)
Alteration
Depth
Reference
Depth
Total
Depth
Alteration
Frequency
(%)
Alteration
Depth
Reference
Depth
CD8A 2 87015659 missense C217Y tGt/tAt 87 0 0 87 111 43.2 48 63
MON1A 3 49948000 stop-gained Q408* Cag/Tag 115 0 0 115 107 60.7 65 42
SPOCK3 4 167713403 missense R212S agA/agT 99 0 0 99 138 47.8 66 72
PCDHGA1 5 140711186 missense Y312C tAc/tGc 132 0 0 132 157 49 77 80
MKRN1 7 140156549 missense R297C Cgc/Tgc 78 0 0 78 92 42.4 39 53
COL14A1 8 121357635 missense A1637V gCc/gTc 178 0 0 178 201 26.4 53 148
YY1 14 100706051 missense G157D gGc/gAc 136 0 0 136 155 50.3 78 77
SLFN11 17 33690713 missense Q38H caG/caC 134 0 0 134 173 42.8 74 99
NFE2L1 17 46136797 missense R705C Cgc/Tgc 240 0 0 240 275 30.2 83 192
BPTF 17 65928063 missense V2189M Gtg/Atg 259 0 0 259 337 31.8 107 230
ZNF461 19 37147428 missense P52A Cca/Gca 38 0 0 38 51 45.1 23 28
CEACAM6 19 42265405 missense R225C Cgc/Tgc 147 0 0 147 210 46.2 97 113
PLCB4 20 9318677 missense S63Y tCc/tAc 50 0 0 50 75 40 30 45
RBM39 20 34309684 missense G268V gGg/gTg 56 0 0 56 62 45.2 28 34
DLGAP4 20 35075259 stop-gained Q523* Cag/Tag 54 0 0 54 76 53.9 41 35
SNX21 20 44462984 stop-gained R56* Cga/Tga 155 0 0 155 197 42.1 83 114
CDH22 20 44803302 missense G777D gGc/gAc 110 0 0 110 116 56 65 51
Prental HCT116 Resistant Clone
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Table 3. TaqMan Gene Expression Assays (Life Technologies) for Quantitative 
RT-PCR. 
 
Gene name Probe # 
RBM39 Hs00705337_s1 
ZNF177 Hs00185695_m1 
RBM15 Hs00368498_s1 
ITGA2 Hs00158148_m1 
SLC7A11 Hs00204928_m1 
GSS Hs00609286_m1 
CCNH Hs00236923_m1 
VEGFA (E5-E6) Hs00903127_m1 
VEGFA (E5-E7) Hs00900057_m1  
VEGFA (E5-E8) Hs03929005_m1  
VEGFA Hs00900055_m1  
DCAF15 Hs00384913_m1 
DDB1 Hs01096550_m1 
GAPDH Hs99999905_m1 
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Supplementary Table 4. siRNA oligonucleotides. 
 
Target gene Catalog # Target sequence 
RBM39 J-011965-05 GAUAACAGCAGCAUAUGUA 
RBM39 J-011965-06 GCAGGUGGUUUGCUGGUAA 
RBM39 J-011965-07 GAUGGGAUACCGAGAUUAA 
RBM39 J-011965-08 GACAGAAAUUCAAGACGUU 
DCAF15 J-031237-15 UGGCGGACAGCGAGCGAUA 
DCAF15 J-031237-16 UCACACUAGACUUCGAAUA 
DCAF15 J-031237-17 CCUCCAAGGUCAUCGUCUU 
DCAF15 J-031237-18 AUGAGUUGGAGGACGACAA 
DDB1 J-012890-06 CACUAGAUCGCGAUAAUAA 
DDB1 J-012890-07 GAAGGUUCUUUGCGGAUCA 
DDB1 J-012890-08 CAUCGACGGUGACUUGAUU 
DDB1 J-012890-09 CAUCUCGGCUCGUAUCUUG 
CUL4A J-012610-07 GCAUGUGGAUUCAAAGUUA 
CUL4B J-017965-08 GCUAUUGGCCGACAUAUGU 
Non-targeting D-001810-01-05 UGGUUUACAUGUCGACUAA 
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Table 5. Primers used in the amplicon sequencing. 
RBM39-AmpliSeq-F ACACTCTTTCCCTACACGACGCTCTTCCGATCTGGC
TTTATGTGGGCTCATTAC 
RBM39-AmpliSeq-R2 
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTAT
GTAGTTATACTCAGATCAACAACCTAC 
DCAF15-1F-MiF 
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCCA
TTGCCAAAGCCAAGGAGTTTG 
DCAF15-2R-MiR 
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCG
CTCACCATCCTCCGGCTCCGTC 
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Table 6. Primers used for indexing. 
P5F 
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCT 
P7R-Index1 CAAGCAGAAGACGGCATACGAGATCGTGATGTGAC
TGGAGTTCAGACGTGTGCTCTTCCGATCT 
P7R-Index14 CAAGCAGAAGACGGCATACGAGATGGAACTGTGAC
TGGAGTTCAGACGTGTGCTCTTCCGATCT 
P7R-Index15 
CAAGCAGAAGACGGCATACGAGATTGACATGTGAC
TGGAGTTCAGACGTGTGCTCTTCCGATCT 
P7R-Index16 CAAGCAGAAGACGGCATACGAGATGGACGGGTGAC
TGGAGTTCAGACGTGTGCTCTTCGATCT 
P7R-Index18 
CAAGCAGAAGACGGCATACGAGATGCGGACGTGAC
TGGAGTTCAGACGTGTGCTCTTCCGATCT 
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Chapter III 
 
Concluding remarks 
Regulation of protein degradation is an essential mechanism to maintain cell 
homeostasis and to regulate cell fate. Ubiquitin is well conserved and widely distributed 
76 amino-acid tag of protein, and the protein ubiquitination is responsible for much of 
the regulated proteolysis in the cell. In spite of large efforts to control ubiquitin ligase 
by a small molecule as attempts for drug discovery and development, only a few drugs 
which targets the ubiquitin system have been approved50,51. 
In chapter II, I revealed the anticancer mechanism of a series of the sulfonamide 
small compounds which are developed as a candidate of pharmaceutical drug because 
they show anticancer activities in preclinical models and clinical benefits in a small 
subset of patients but the primary target molecule and mechanism of action is not 
understood. I revealed those sulfonamide derivatives inducing protein complex 
assembly between CAPERα and CRL4DCAF15 to lead the ubiquitination and proteasomal 
degradation of a splicing factor CAPERα8. A single amino acid substitution of CAPERα 
conferred resistance against sulfonamide-induced CAPERα degradation and cell-growth 
inhibition, suggesting that CAPERα degradation is a key biochemical activity that 
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underlies the anticancer properties of these compounds. CAPERα is known to have 
similar protein motifs with U2AF2 splicing factor and to regulate divers RNA splicing 
events32,35. I confirmed chemical knockdown of CAPERα by E7820 induces the 
significant change in the alternative splicing of VEGFA and the broad gene expression 
changes which may cause anti-proliferative effect in cells. Thus, the anticancer 
mechanism of the sulfonamide derivatives, in addition to the mechanism of IMiDs, 
demonstrates a novel feature of the ubiquitin ligase as a target of small molecule ligands 
that induce selective protein ubiquitination and degradation to regulate gene expression, 
mRNA splicing, and cell fate. 
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